ZA95679B - Products containing G-CSF and TNF binding protein - Google Patents

Products containing G-CSF and TNF binding protein

Info

Publication number
ZA95679B
ZA95679B ZA95679A ZA95679A ZA95679B ZA 95679 B ZA95679 B ZA 95679B ZA 95679 A ZA95679 A ZA 95679A ZA 95679 A ZA95679 A ZA 95679A ZA 95679 B ZA95679 B ZA 95679B
Authority
ZA
South Africa
Prior art keywords
csf
binding protein
pharmaceutically acceptable
tnf binding
acceptable salt
Prior art date
Application number
ZA95679A
Other languages
English (en)
Inventor
Gottfried Alber
Peter Angehrn
Original Assignee
Hoffman La Roche A G F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffman La Roche A G F filed Critical Hoffman La Roche A G F
Publication of ZA95679B publication Critical patent/ZA95679B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02Local antiseptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/81Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA95679A 1994-02-04 1995-01-27 Products containing G-CSF and TNF binding protein ZA95679B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810059 1994-02-04

Publications (1)

Publication Number Publication Date
ZA95679B true ZA95679B (en) 1995-08-08

Family

ID=8218199

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95679A ZA95679B (en) 1994-02-04 1995-01-27 Products containing G-CSF and TNF binding protein

Country Status (16)

Country Link
US (2) US5776895A (fr)
EP (1) EP0668077B1 (fr)
JP (1) JP2765807B2 (fr)
CN (1) CN1097468C (fr)
AT (1) ATE202709T1 (fr)
AU (1) AU693833B2 (fr)
BR (1) BR9500436A (fr)
CA (1) CA2139385C (fr)
DE (1) DE69521536T2 (fr)
DK (1) DK0668077T3 (fr)
ES (1) ES2160643T3 (fr)
GR (1) GR3036774T3 (fr)
NZ (1) NZ270422A (fr)
PT (1) PT668077E (fr)
RU (1) RU2139084C1 (fr)
ZA (1) ZA95679B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054201A1 (fr) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Proteine 8 apparentee au recepteur du facteur de necrose tumorale humain
AU749332B2 (en) * 1997-11-07 2002-06-27 Uab Research Foundation Method for the augmentation of gene expression
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
EP1100529B2 (fr) * 1998-07-30 2010-08-25 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Amelioration de la guerison des blessures par la thymosine beta 4
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
US20080108560A1 (en) * 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
ES2304602T3 (es) 2003-02-28 2008-10-16 Ares Trading S.A. Formulaciones liquidas de la proteina de union al factor de necrosis tumoral tbp-1.
MX2009012968A (es) * 2007-06-06 2010-04-01 Domantis Ltd Polipeptidos, dominios variables de anticuerpo y antagonistas.
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
NZ600382A (en) * 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
AR113756A1 (es) * 2017-10-11 2020-06-10 Ambrx Inc Variantes porcinas de g-csf y sus usos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
EP1018552B1 (fr) * 1985-08-23 2006-07-05 Kirin-Amgen, Inc. Production du Facteur pluripotent de stimulation de colonies de granulocytes
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP0939121B2 (fr) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. Protéines liant le TNF
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン,インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
WO1993011793A1 (fr) * 1991-12-17 1993-06-24 Schering Corporation Utilisation de la combinaison du facteur de necrose anti-tumeur et de l'interleukine-6 dans le traitement du choc septique
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JP3720352B2 (ja) * 1992-05-05 2005-11-24 アエレス バイオメディカル リミティド P−セレクチンに対する抗体及びその利用

Also Published As

Publication number Publication date
DE69521536T2 (de) 2002-04-18
CN1097468C (zh) 2003-01-01
AU693833B2 (en) 1998-07-09
US5750503A (en) 1998-05-12
CN1111158A (zh) 1995-11-08
AU1146295A (en) 1995-08-17
NZ270422A (en) 1996-06-25
DK0668077T3 (da) 2001-10-08
EP0668077B1 (fr) 2001-07-04
CA2139385C (fr) 2001-12-25
PT668077E (pt) 2001-12-28
RU2139084C1 (ru) 1999-10-10
BR9500436A (pt) 1995-10-17
RU95101385A (ru) 1996-12-27
GR3036774T3 (en) 2002-01-31
ATE202709T1 (de) 2001-07-15
DE69521536D1 (de) 2001-08-09
EP0668077A1 (fr) 1995-08-23
JP2765807B2 (ja) 1998-06-18
ES2160643T3 (es) 2001-11-16
CA2139385A1 (fr) 1995-08-05
US5776895A (en) 1998-07-07
JPH07258300A (ja) 1995-10-09

Similar Documents

Publication Publication Date Title
AU693833B2 (en) Products containing G-CSF and TNF binding protein
BE2018C038I2 (fr)
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
EP0734723A4 (fr) Composition therapeutique utile pour traiter l'hyperparathyroidie d'un patient en dialyse artificielle
EP0347899A3 (en) Pharmaceutical compositions on egg shell basis and their preparation and use
EP1006793A4 (fr) Compositions pour traiter l'arythmie et procedes de traitement
GR3021813T3 (en) Method of treating alopecia
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
HK124595A (en) Anthocyanidins for the treatment of ophthalmic diseases
MY104124A (en) Therapeutic compounds.
EP0343671A3 (en) Pharmaceutical composition for the treatment of skin wounds
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
NZ268039A (en) Use of efaroxan in treating parkinson's disease
IL126158A0 (en) Method for treating substance abuse
EP0384302A3 (fr) Usage d'ubenimex dans la fabrication d'un médicament pour le traitement du syndrome myélodysplastique
WO1999013894A3 (fr) Utilisation d'ifn-alpha et d'amantadine dans le traitement de l'hepatite c chronique
CA2147749A1 (fr) Agent therapeutique contre les maladies du parodonte
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
RU98114855A (ru) Использование 1-энантиомер центхромана для получения фармацевтической композиции для лечения и профилактики рака молочной железы